February 19, 2013
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Abstract Bendamustine, active in multiple myeloma (MM), is a bifunctional mechlorethamine derivative with alkylating properties. Bortezomib, approved to [...]
November 19, 2012
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
Leuk Res. 2012 Nov;36(11):1422-7. doi: 10.1016/j.leukres.2012.07.018. Epub 2012 Aug 17. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR. Abstract Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have anti-MM activity in combination with dexamethasone or lenalidomide. However, no data exists on the anti-MM [...]
November 9, 2012
Myeloma Cure Panel Broadcast – Dr. James Berenson will discuss Multiple Myeloma disease control Without Transplant
Dr. Berenson will be the featured Myeloma Cure Talk Panel member on this November 29th, 2012 @ 6:00 PM EST broadcast. You can sign up for the broadcast at the following link: http://trialx.com/curetalk/panels/myeloma-cure-panel-with-dr-james-berenson-on-29-november-2012-6pm-est/ The discussion will cover Dr. Berenson’s multiple myeloma treatment philosophy and preferred treatment protocols. He has been known for protocols that do not include [...]
October 26, 2012
Updates in the Treatment of Multiple Myeloma
UpdatesinTreatmentMM
September 18, 2012
Comments Off
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Abstract Although TNFRSF17 (also [...]
June 1, 2012
Dedication of “Determination”
The Institute for Myeloma & Bone Cancer Research (IMBCR) is pleased to announce the dedication of a newly designed artwork for IMBCR. Artist, Ted Kirby, named the artwork “Determination”, in honor of all those who are determined to cure Multiple Myeloma. Please join us for the dedication and to meet the artist, followed by a [...]
May 28, 2012
Understanding Myeloma News About Secondary Cancers and Clotting
Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
November 23, 2011
Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trails for cnacer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, CA on December 10-13, 2011.
March 19, 2011
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. Abstract Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown anti-tumor activity in preclinical studies in both solid and hematological malignancies. We evaluated the [...]
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
March 28, 2013
0 Comments